Prostaglandins and their receptors in eosinophil function and as therapeutic targets

14Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Of the known prostanoid receptors, human eosinophils express the prostaglandin D 2 (PGD 2 ) receptors DP1 [also D-type prostanoid (DP)] and DP2 (also chemoattractant receptor homologous molecule, expressed on Th2 cells), the prostaglandin E2 receptors EP2 and EP4, and the prostacyclin (PGI 2 ) receptor IP. Prostanoids can bind to either one or multiple receptors, characteristically have a short half-life in vivo, and are quickly degraded into metabolites with altered affinity and specificity for a given receptor subtype. Prostanoid receptors signal mainly through G proteins and naturally activate signal transduction pathways according to the G protein subtype that they preferentially interact with. This can lead to the activation of sometimes opposing signaling pathways. In addition, prostanoid signaling is often cell-type specific and also the combination of expressed receptors can influence the outcome of the prostanoid impulse. Accordingly, it is assumed that eosinophils and their (patho-)physiological functions are governed by a sensitive prostanoid signaling network. In this review, we specifically focus on the functions of PGD 2 , PGE 2 , and PGI 2 and their receptors on eosinophils. We discuss their significance in allergic and non-allergic diseases and summarize potential targets for drug intervention.

Cite

CITATION STYLE

APA

Peinhaupt, M., Sturm, E. M., & Heinemann, A. (2017). Prostaglandins and their receptors in eosinophil function and as therapeutic targets. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2017.00104

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free